Recursion Pharmaceuticals (NASDAQ:RXRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Recursion Pharmaceuticals (NASDAQ:RXRX) from a sell rating to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Several other brokerages have also recently commented on RXRX. Morgan Stanley set a $5.90 target price on Recursion Pharmaceuticals in a report on Friday, October 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, October 15th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $8.18.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX opened at $3.81 on Friday. Recursion Pharmaceuticals has a 52-week low of $2.77 and a 52-week high of $5.24. The firm has a 50 day moving average price of $3.78 and a two-hundred day moving average price of $3.51. The stock has a market cap of $2.04 billion, a P/E ratio of -4.23 and a beta of 1.15.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). The firm had revenue of $18.55 million during the quarter, compared to the consensus estimate of $14.81 million. Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 47.85%. During the same quarter last year, the firm earned ($0.36) earnings per share. Analysts predict that Recursion Pharmaceuticals will post -0.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, Director Robert Hershberg sold 25,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total value of $125,000.00. Following the completion of the sale, the director directly owned 162,156 shares of the company’s stock, valued at approximately $810,780. The trade was a 13.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total transaction of $78,876.16. Following the transaction, the chief executive officer owned 2,072,890 shares in the company, valued at $7,296,572.80. This represents a 1.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 167,408 shares of company stock worth $701,276. 6.65% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RXRX. MCF Advisors LLC acquired a new stake in Recursion Pharmaceuticals in the second quarter valued at approximately $27,000. Jacobi Capital Management LLC acquired a new position in shares of Recursion Pharmaceuticals during the third quarter worth approximately $31,000. Fund Advisors of America Inc FL acquired a new position in shares of Recursion Pharmaceuticals during the second quarter worth approximately $45,000. Sequoia Financial Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 51.5% in the 1st quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after purchasing an additional 5,156 shares in the last quarter. Finally, QRG Capital Management Inc. bought a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth $47,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments.

The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.

Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion was co-founded by Chris Gibson, who serves as its chief executive officer.